Compare · head to head
Bayer vs Novartis
Novartis ranks higher overall — 360 rank 38 vs 15.
Bayer leads on Value (60 vs 51) and Sentiment (60 vs 39). Novartis leads on Quality (65 vs 31) and Safety (44 vs 16). The two are close on Growth.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | Germany | Switzerland |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | XX-Large | XX-Large |
| ISIN | DE000BAY0017 | CH0012005267 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 15 | 38 |
| Value | 60 | 51 |
| Quality | 31 | 65 |
| Growth | 40 | 37 |
| Safety | 16 | 44 |
| Sentiment | 60 | 39 |
| Quality details | ||
| Profitability | 14 | 76 |
| Cash Truth | 48 | 55 |
Bayer vs HaleonBayer vs PerrigoBayer vs Faes FarmaBayer vs GlaxoSmithKline PharmaceuticalsAdd a third stock →
Full analyses: Bayer · Novartis
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100